Researchers reviewed eight existing clinical trials involving 541 older adults with Type 2 diabetes. They wanted to understand how a class of diabetes drugs called SGLT2 inhibitors affects body composition—specifically body weight, fat mass, and muscle mass. This type of study, called a meta-analysis, pools data from multiple smaller studies to look for overall patterns.
The analysis found that taking SGLT2 inhibitors was linked to significant reductions in body weight and fat mass. It also showed a smaller, but still measurable, reduction in muscle mass. The data on fat and muscle loss came from studies that were somewhat different from each other, which adds some uncertainty to the exact size of these effects.
No safety concerns or side effects were reported in this specific review. The main reason for caution is that the observed loss of muscle mass, while small, could be important for older adults who are already at risk for losing muscle strength. This review shows a link, but it does not prove the drugs directly cause muscle loss. Patients should not stop or change their medication based on this review alone, but it highlights why doctors might monitor muscle health in older patients on these drugs.
